产品
编 号：F304792
分子式：C23H25NO2
分子量：347.45
分子式：C23H25NO2
分子量：347.45
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 28360-49-8
产品详情
生物活性：
Mahanine is a carbazole alkaloid with various biological properties. Mahanine is a potent anticancer agent against different types of cancer cells. Mahanine exhibits antileishmanial activity and can be used for Leishmania infection research research.
体内研究：
Mahanine (oral gavage; 20?mg/kg/40 mg/kg; b.w/day; 5 days) results in 89.1±4.1% reductions in parasite burden at 20?mg/kg, and leads to 96.2±0.3% reductions in parasite burden at 40?mg/kg in a well-established acute model to control?Leishmania?infection.Animal Model:Balb/c mice with virulent AG83 promastigotes
Dosage:20?mg/kg-40 mg/kg
Administration:oral gavage; 20?mg/kg/40 mg/kg; b.w/day; 5 days
Result:Had the potential to clear parasite burden?in vivo.Exhibited almost complete reduction of parasite burden, upregulation of NO/iNOS/ROS/IL-12 and T?cell proliferation in vivo.
体外研究：
Mahanine (0-50?μM; 24 or 48 hours) induces a dose-dependent decrease in cell viability of AG83 promastigotes after 24?hr and 48 hr; the IC50?values were 16.7±1.7?μM and 11.5±0.8?μM respectively. In a drug resistant GE1 strain, Mahanine treatment exhibits dose-dependent cell death in 24 and 48 hr treatment with IC50?values 40.3±2.2?μM and 29.1±1.3?μM respectively.Mahanine (5.0 and 10?μM; 24 hours) exhibits increased accumulation of cells at G2/M phase being 39.0±1.90% and 41.0±2.10% respectively compared to untreated promastigotes (35.3?±?2.60%) in AG83 promastigote?.Mahanine (25?μM; 24 hours) exhibitssignificantly increased intracellular ROS level within 20?min (MFI being 889?±?26) which reached to 1288?±?56 after one hour compared to the basal level (604?±?34) in untreated promastigote. H2DCFDA positivity was measured by FACS.
Mahanine is a carbazole alkaloid with various biological properties. Mahanine is a potent anticancer agent against different types of cancer cells. Mahanine exhibits antileishmanial activity and can be used for Leishmania infection research research.
体内研究：
Mahanine (oral gavage; 20?mg/kg/40 mg/kg; b.w/day; 5 days) results in 89.1±4.1% reductions in parasite burden at 20?mg/kg, and leads to 96.2±0.3% reductions in parasite burden at 40?mg/kg in a well-established acute model to control?Leishmania?infection.Animal Model:Balb/c mice with virulent AG83 promastigotes
Dosage:20?mg/kg-40 mg/kg
Administration:oral gavage; 20?mg/kg/40 mg/kg; b.w/day; 5 days
Result:Had the potential to clear parasite burden?in vivo.Exhibited almost complete reduction of parasite burden, upregulation of NO/iNOS/ROS/IL-12 and T?cell proliferation in vivo.
体外研究：
Mahanine (0-50?μM; 24 or 48 hours) induces a dose-dependent decrease in cell viability of AG83 promastigotes after 24?hr and 48 hr; the IC50?values were 16.7±1.7?μM and 11.5±0.8?μM respectively. In a drug resistant GE1 strain, Mahanine treatment exhibits dose-dependent cell death in 24 and 48 hr treatment with IC50?values 40.3±2.2?μM and 29.1±1.3?μM respectively.Mahanine (5.0 and 10?μM; 24 hours) exhibits increased accumulation of cells at G2/M phase being 39.0±1.90% and 41.0±2.10% respectively compared to untreated promastigotes (35.3?±?2.60%) in AG83 promastigote?.Mahanine (25?μM; 24 hours) exhibitssignificantly increased intracellular ROS level within 20?min (MFI being 889?±?26) which reached to 1288?±?56 after one hour compared to the basal level (604?±?34) in untreated promastigote. H2DCFDA positivity was measured by FACS.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备